Institut Génétique Nantes Atlantique - Academic Profile

Publications

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka , Seiji Yano , Giuseppe Giaccone +17 more

Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine ki...

2003 Journal of Clinical Oncology 2877 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

Philippe Moreau , Federica Cavallo , Xavier Leleu +7 more

2011 Leukemia 56 citations

Affiliated Researchers

Jean‐Luc Harousseau

Institut Génétique Nantes Atlantique

Frédéric Rolland

Institut Génétique Nantes Atlantique

Institution Info

Type: facility
Country: FR
Publications: 3
Citations: 4,530

External Links

Identifiers

ROR: https://ror.org/024h0z890